What does agomelatine bring to treatment of depression?an up-to-date review

Basit Öğe Kaydı
dc.authorscopusid15753416700
dc.authorscopusid14627750100
dc.authorscopusid55370096000
dc.authorscopusid56288169800
dc.authorscopusid14627787400
dc.authorscopusid14627498100
dc.contributor.authorCerit, Cem
dc.contributor.authorYalu?, Irem
dc.contributor.authorAkpinar, Esma
dc.contributor.authorTalas, Anil
dc.contributor.authorTufan, Ali Evren
dc.contributor.authorÖzten, Eylem
dc.date.accessioned2024-09-25T19:44:00Z
dc.date.available2024-09-25T19:44:00Z
dc.date.issued2013
dc.departmentAbant İzzet Baysal Üniversitesien_US
dc.description.abstractIn this article literature related to the promises of agomelatine, an antidepressant with melatonergic MT-1 and MT- 2 receptor agonism and seratoninergic 5-HT2c receptor antagonism in the context of depression treatment is reviewed. Although the results of studies on the efficacy of agomelatine are contrary, it can be stressed that the efficacy of agomelatine should be at least similar to widely used antidepressants. Furthermore the favorable effect of agomelatine on sleep and the early onset of efficacy should contribute to the outcome of therapy. The favorable effect of agomelatine on the circadian rhythm which has influence on substantial biological systems like sleepwake cycle, endocrine hormone secretion and body temperature appears to be interesting. Somnolence should be noted as a more frequent adverse event of agomelatine than other antidepressants. Furthermore the absence of weight gain and sexual adverse events should influence the adherence to therapy. Liver enzyme elevations can emerge during agomelatine therapy. Abrupt discontinuation of agomelatine does not appear to bring about evident discontinuation symptoms.en_US
dc.identifier.endpage131en_US
dc.identifier.issn1300-8773
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-84904619883en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage123en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12491/12599
dc.identifier.volume51en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherIstanbul Universitesien_US
dc.relation.ispartofYeni Symposiumen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzYK_20240925en_US
dc.subjectAgomelatineen_US
dc.subjectDepressionen_US
dc.subjectMelatoninen_US
dc.titleWhat does agomelatine bring to treatment of depression?an up-to-date reviewen_US
dc.title.alternativeAgomelatin depresyon tedavisine ne getiriyor? güncel bir gözden geçirme]en_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu